Open
由具跨國背景的臨床醫師與資深技術人員組成，致力於開發具高階產業價值的醫療器材、行動醫療產品。目前兩項產品分別為APrevent® VOIS全球唯一用於治療聲門閉鎖不全的可調式咽喉植入物，以及AiSpeak人工智慧語音轉換系統。
APrevent is dedicated to providing minimally invasive and innovative technologies for voice disorders, which are patient-orientated, physician friendly and most of all to improve life quality of patients.
First innovated product, Vocal Implant System (VOIS), is used for patients with glottic insufficiency. Feature of VOIS includes: (1) Intra-and post -operative adjustable; (2)Achieve vocal fold complete closure; (3)Design for ultrasound guided injection; (4)Individualized optimal results for patients.
Sencod product, APrevent Intelligible Speak (AiSpeeak), is an innovative solution providing patients to communicate with their own speech, which transfer dysarthric speech into intelligible speech. Feature of AiSpeak includes:(1) Real-time speech-to-speech conversion; (2)Easy and convenient hands-free operation with own speech; (3)Speech conversion without limitation of vocabularies.; (4)Connection with Internet of Things (IoT) for broader applications."
APrevent is dedicated to providing minimally invasive and innovative technologies for voice disorders, which are patient-orientated, physician friendly and most of all to improve life quality of patients.
First innovated product, Vocal Implant System (VOIS), is used for patients with glottic insufficiency. Feature of VOIS includes: (1) Intra-and post -operative adjustable; (2)Achieve vocal fold complete closure; (3)Design for ultrasound guided injection; (4)Individualized optimal results for patients.
Sencod product, APrevent Intelligible Speak (AiSpeeak), is an innovative solution providing patients to communicate with their own speech, which transfer dysarthric speech into intelligible speech. Feature of AiSpeak includes:(1) Real-time speech-to-speech conversion; (2)Easy and convenient hands-free operation with own speech; (3)Speech conversion without limitation of vocabularies.; (4)Connection with Internet of Things (IoT) for broader applications."